These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 28378734)

  • 1. [Pharmacoeconomic aspects of macitentan in the therapy of pulmonary arterial hypertension].
    Moiseeva OM; Rudakova AV
    Ter Arkh; 2017; 89(3):72-77. PubMed ID: 28378734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness Analysis of Macitentan in Comparison With Bosentan in the Treatment of Pulmonary Arterial Hypertension in Iran.
    Ekhlasi M; Sheikhi S; Majd ZK; Peiravian F; Yousefi N
    Value Health Reg Issues; 2023 Mar; 34():78-85. PubMed ID: 36599206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
    Chen YF; Jowett S; Barton P; Malottki K; Hyde C; Gibbs JS; Pepke-Zaba J; Fry-Smith A; Roberts J; Moore D
    Health Technol Assess; 2009 Oct; 13(49):1-320. PubMed ID: 19863849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Dynamics of the clinical functional and hemodynamic profile of patients with pulmonary arterial hypertension with initial monotherapy with endothelin receptor antagonists: bosentan vs. macitentan].
    Martynyuk TV; Aleevskaya AM
    Kardiologiia; 2020 Aug; 60(7):28-35. PubMed ID: 33155938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Focus on Macitentan in the Treatment of Pulmonary Arterial Hypertension.
    Bedan M; Grimm D; Wehland M; Simonsen U; Infanger M; Krüger M
    Basic Clin Pharmacol Toxicol; 2018 Aug; 123(2):103-113. PubMed ID: 29719121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost-effectiveness of bosentan in the United Kingdom for patients with pulmonary arterial hypertension of WHO functional class III.
    Stevenson MD; Macdonald FC; Langley J; Hunsche E; Akehurst R
    Value Health; 2009; 12(8):1100-5. PubMed ID: 19558373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerability of Switch to Macitentan from Bosentan in Pulmonary Arterial Hypertension.
    Safdar Z; Thakur A; Frost A
    South Med J; 2017 Mar; 110(3):223-228. PubMed ID: 28257550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells.
    Gatfield J; Mueller Grandjean C; Sasse T; Clozel M; Nayler O
    PLoS One; 2012; 7(10):e47662. PubMed ID: 23077657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-utility analysis of Macitentan Vs. Bosentan in pulmonary atrial hypertension.
    Nosrati M; Shahmirzadi NA; Afzali M; Zaboli P; Rouhani H; Hamedifar H; Hajimiri M
    J Family Med Prim Care; 2020 Jul; 9(7):3634-3638. PubMed ID: 33102342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis.
    Dranitsaris G; Mehta S
    Appl Health Econ Health Policy; 2009; 7(1):43-59. PubMed ID: 19558194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment.
    Grünig E; Ohnesorge J; Benjamin N; Burhenne J; Enderle Y; Egenlauf B; Fischer C; Harutyunova S; Huppertz A; Klose H; Haefeli WE
    Respiration; 2017; 94(1):26-37. PubMed ID: 28494463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost Effectiveness of First-Line Oral Therapies for Pulmonary Arterial Hypertension: A Modelling Study.
    Coyle K; Coyle D; Blouin J; Lee K; Jabr MF; Tran K; Mielniczuk L; Swiston J; Innes M
    Pharmacoeconomics; 2016 May; 34(5):509-20. PubMed ID: 26739957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bosentan or Macitentan Therapy in Chronic Thromboembolic Pulmonary Hypertension?
    van Thor MCJ; Ten Klooster L; Snijder RJ; Kelder JC; Mager JJ; Post MC
    Lung; 2019 Dec; 197(6):753-760. PubMed ID: 31583452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative adherence of macitentan versus ambrisentan and bosentan in Australian patients with pulmonary arterial hypertension: a retrospective real-world database study.
    Lau E; Kotlyar E; Makanji Y; Yu DY; Tan JY; Casorso J; Kouhkamari MH; Lim S; Wu DB; Bloomfield P
    J Med Econ; 2024; 27(1):596-604. PubMed ID: 38488130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of pharmacological activity of macitentan and bosentan in preclinical models of systemic and pulmonary hypertension.
    Iglarz M; Bossu A; Wanner D; Bortolamiol C; Rey M; Hess P; Clozel M
    Life Sci; 2014 Nov; 118(2):333-9. PubMed ID: 24582812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment patterns and resource utilization and costs among patients with pulmonary arterial hypertension in the United States.
    Angalakuditi M; Edgell E; Beardsworth A; Buysman E; Bancroft T
    J Med Econ; 2010; 13(3):393-402. PubMed ID: 20608882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Macitentan and Bosentan on Right Ventricular Remodeling in a Rat Model of Non-vasoreactive Pulmonary Hypertension.
    Iglarz M; Landskroner K; Bauer Y; Vercauteren M; Rey M; Renault B; Studer R; Vezzali E; Freti D; Hadana H; Schläpfer M; Cattaneo C; Bortolamiol C; Weber E; Whitby BR; Delahaye S; Wanner D; Steiner P; Nayler O; Hess P; Clozel M
    J Cardiovasc Pharmacol; 2015 Nov; 66(5):457-67. PubMed ID: 26230396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The new endothelin receptor antagonist macitentan: Prospects for therapy of pulmonary arterial hypertension].
    Avdeev SN
    Ter Arkh; 2016; 88(7):89-97. PubMed ID: 27459621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension.
    Aypar E; Alehan D; Karagöz T; Aykan HH; Ertugrul İ
    Cardiol Young; 2018 Apr; 28(4):542-547. PubMed ID: 29233198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the combination of endothelin receptor antagonists (ERA) and phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension (PAH) in pathologic human pulmonary arteries in an ex-vivo organ bath model.
    Englert L; Stadlbauer C; Spaeth M; Hofmann HS; Schneider C; Hatz RA; Preissler G; Michel S; Golovchenko S; Ried M; Hoenicka M
    Pulm Pharmacol Ther; 2021 Feb; 66():101985. PubMed ID: 33359621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.